Abstract
Diabetes mellitus (diabetes Greek, pass through/siphon; mellitus Latin, honey sweet) is a heterogeneous, multifactorial metabolic disorder characterized by chronic hyperglycemia. This is in part because insulin secretion is insufficient to maintain blood glucose levels in a physiological range [1]. On the one hand, diabetes can be diagnosed based on classical symptoms, i.e., polyuria (excessive production of urine) and polydipsia (excessive fluid intake) due to osmotic diuresis following glucosuria. The presence of glucose in urine is caused by blood glucose levels exceeding the capacity of renal tubular sodium-glucose linked transporters (SGLTs) to reabsorb glucose from the primary urine. On the other hand, the World Health Organization (WHO) criteria define diabetes either as a fasting blood glucose level at or above 7 mmol/l or as a level at or above 11.1 mmol/l 2 h post glucose challenge during an oral glucose tolerance test (2-h plasma glucose). The WHO further describes criteria of a prediabetes that comes with a strongly increased risk to develop diabetes. These include an impaired fasting blood glucose between 6.1 mmol/l and 6.9 mmol/l. In addition, an impaired glucose tolerance as indicated by a 2-h plasma glucose between 7.8 mmol/l and 11 mmol/l or glycated hemoglobin between 5.7 and 6.4 % points to prediabetes [2].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:1293–1300
WHO;IDF (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia; Report of a WHO/IDF consultation; ISBN: 978-92-4-159493-6
Sherwin R, Jastreboff AM (2012) Year in diabetes 2012: the diabetes tsunami. J Clin Endocrinol Metab 97:4293–4301
American Diabetes Association (2012) Diagnosis and classification of diabetes mellitus. Diabetes Care 35(Suppl 1):S64–S71
American Diabetes Association (2004) Gestational diabetes mellitus. Diabetes Care 27(Suppl 1):S88–S90
Boitard C (2012) Pancreatic islet autoimmunity. Presse Med 41:e636–e650
Peng H, Hagopian W (2006) Environmental factors in the development of type 1 diabetes. Rev Endocr Metab Disord 7:149–162
Classen JB, Classen DC (2001) Vaccines and the risk of insulin-dependent diabetes (IDDM): potential mechanism of action. Med Hypotheses 57:532–538
Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846
Kwon H, Pessin JE (2013) Adipokines mediate inflammation and insulin resistance. Front Endocrinol 4:71
Coppari R, Bjorbaek C (2012) Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov 11:692–708
Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333–1346
Robertson RP, Harmon J, Tran PO, Poitout V (2004) Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53(Suppl 1):S119–S124
Siren R, Eriksson JG, Vanhanen H (2012) Waist circumference a good indicator of future risk for type 2 diabetes and cardiovascular disease. BMC Public Health 12:631
Weir GC, Cavelti-Weder C, Bonner-Weir S (2011) Stem cell approaches for diabetes: towards beta cell replacement. Genome Med 3:61
Laakso M (1999) Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48:937–942
Yamagishi S (2011) Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 46:217–224
Furukawa M, Gohda T, Tanimoto M, Tomino Y (2013) Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy. Scientific World Journal 2013:928197
Sho-ichi Y (2010) Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 46:217–224
Costa PZ, Soares R (2013) Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life sci 92:1037–1045
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298:1180–1188
Black C et al (2007) Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 18;(2):CD004654
Butler AE et al (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62:2595–2604
Riser Taylor S, Harris KB (2013) The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 33:984–999
Yaturu S (2013) Insulin therapies: current and future trends at dawn. World J Diab 4:1–7
Nathan DM et al (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193–203
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Wien
About this chapter
Cite this chapter
Welters, A., Lammert, E. (2014). Diabetes Mellitus. In: Lammert, E., Zeeb, M. (eds) Metabolism of Human Diseases. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0715-7_26
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0715-7_26
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0714-0
Online ISBN: 978-3-7091-0715-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)